Amaria, R. ., Prieto, P. ., Tetzlaff, M. ., Reuben, A. ., Andrews, M. ., Ross, M. ., … Wargo, J. . (2018). Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. The Lancet. Oncology, 19(2), 181-193. https://doi.org/10.1016/S1470-2045(18)30015-9